Tags migraine migraine Migraine, and drugs that treat or prevent it.
Theme · 2 companies · 0 report it as a revenue line
Sells it“Ubrelvy (ubrogepant) is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.”
Latest 10-K FY2025 Positive Impairment / charge · Filed Feb 20
Skyrizi and Rinvoq more than offset Humira’s biosimilar losses; acquisition-related charges and a tax-rate reversal kept net earnings flat.
Revenue $61.2B YoY +8.6% Net income $4.2B YoY −1.2% Latest 10-Q Q3 FY2026 Positive · Filed Nov 3
Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.
Revenue $17.4B YoY +10.3% Net income $4.2B vs $186.0M year ago Latest 8-K Leadership change · Filed Nov 2
Jennifer L. Davis resigned from AbbVie’s board following her appointment as Align Technology CEO.
Latest 8-K Positive Earnings Guidance raised Impairment / charge · Filed Oct 30
Skyrizi and Rinvoq growth offsets Humira declines; FY2026 adjusted EPS guidance raised to $13.95–$13.99
Latest 8-K Guidance reaffirmed Impairment / charge Deal completed · Filed Sep 3
Closed ≈$10.9B Apogee acquisition, adding late-stage zumilokibart for atopic dermatitis and an asthma combination candidate
Latest 8-K Debt financing · Filed Aug 18
Debt offering completed to help fund the Apogee Therapeutics acquisition and related costs.
Latest 8-K Deal pending · Filed Jun 22
Proposed Apogee acquisition adds clinical-stage atopic dermatitis and asthma programs, with near-term adjusted EPS dilution.
Latest 8-K Shareholder vote · Filed May 12
Bid to eliminate supermajority voting failed despite 98.9% support among votes cast for or against.
Sells it“Migraine product portfolio: Nurtec ODT/Vydura and Zavzpret.”
Latest 10-K FY2025 Impairment / charge · Filed Feb 26
Paxlovid and Comirnaty declines masked non-COVID growth; the Metsera deal targets obesity as patent losses loom.
Revenue $62.6B YoY −1.6% Net income $7.8B YoY −3.2% Latest 10-Q Q3 FY2026 Mixed Impairment / charge · Filed Nov 3
Eliquis and Padcev gains counter COVID-19 declines, but pipeline write-downs expose risks in replacing aging franchises.
Revenue $16.6B YoY −0.4% Net income $3.2B YoY −8.4% Latest 8-K CEO/CFO change · Filed Nov 3
Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.
Latest 8-K Positive Earnings CEO/CFO change Guidance raised Impairment / charge · Filed Nov 3
Raised FY2026 guidance to $62B–$64B revenue and $2.95–$3.05 adjusted EPS despite falling Paxlovid and Comirnaty sales.
Latest 8-K Earnings Guidance reaffirmed Legal / investigation · Filed May 5
Padcev and Eliquis growth helped offset sharp Comirnaty and Paxlovid declines; full-year guidance stays unchanged.
Latest 8-K Shareholder vote Executive pay · Filed Apr 27
Shareholders approved the amended stock plan and executive pay but rejected an independent chair proposal.
No companies have a recent 8-K matching these events. Show all 8-K events
No companies in the selected roles.